Two scientists who discovered how to fight cancer using the body’s immune system have won the 2018 Nobel Prize for physiology or medicine, BBC reported.
The work, by Professor James P Allison from the US and Professor Tasuku Honjo from Japan, has led to treatments for advanced, deadly skin cancer. Immune checkpoint therapy has revolutionised cancer treatment, said the prize-giving Swedish Academy. Experts say it has proved to be “strikingly effective”.
Prof Allison, of the University of Texas, and Prof Honjo, of Kyoto University, will share the Nobel prize sum of nine million Swedish kronor – about $1.01 million or 870,000 euros.
Accepting the prize, Tasuku Honjo told reporters: “I want to continue my research … so that this immune therapy will save more cancer patients than ever.”
Prof Allison said: “It’s a great, emotional privilege to meet cancer patients who’ve been successfully treated with immune checkpoint blockade. They are living proof of the power of basic science, of following our urge to learn and to understand how things work.”
Treating the untreatable
Our immune system protects us from disease, but it has built-in safeguards to stop it from attacking our own tissue.
Some cancers can take advantage of those “brakes” and dodge the attack too.
Allison and Honjo, now both in their 70s, discovered a way to unleash our immune cells to attack tumours by turning off proteins that put the brakes on.
And that led to the development of new drugs which now offer hope to patients with advanced and previously untreatable cancer.
Immune checkpoint therapy is being used by the NHS to treat people with the most serious form of skin cancer, melanoma.
It doesn’t work for everyone, but for some patients it appears to have worked incredibly well, getting rid of the tumour entirely, even after it had started to spread around the body.
Such remarkable results had never been seen before for patients like these.
Doctors have also been using the treatment to help some people with advanced lung cancer.
Prof Charles Swanton, from Cancer Research UK, congratulated the prize winners, saying: “Thanks to this groundbreaking work, our own immune system’s innate power against cancer has been realised and harnessed into treatments that continue to save the lives of patients. For cancers such as advanced melanoma, lung, and kidney, these immune-boosting drugs have transformed the outlook for many patients who had run out of options.
“The booming field of immunotherapy that these discoveries have precipitated is still relatively in its infancy, so it’s exciting to consider how this research will progress in the future and what new opportunities will arise.”